<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279773</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2102</org_study_id>
    <nct_id>NCT00279773</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine the maximum tolerated dose (MTD), dose limiting
      toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid
      leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped due to time dependent drug accumulation
  </why_stopped>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>28 days - dose-escalation; 4 months - dose-expansion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>28 days - dose-escalation; 4 months - dose-expansion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety profile</measure>
    <time_frame>28 days - dose-escalation; 4 months - dose-expansion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of plasma pharmacokinetics and pharmacodynamics</measure>
    <time_frame>28 days - dose-escalation; 4 months - dose-expansion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TKI258 - dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI258 - dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <arm_group_label>TKI258 - dose escalation</arm_group_label>
    <arm_group_label>TKI258 - dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Acute Myeloid Leukemia

          -  Eighteen years of age or older

          -  Life expectancy of at least 2 months

        Exclusion Criteria:

          -  Intracranial disease or epidural disease

          -  Clinically significant cardiac disease

          -  Diabetes mellitus uncontrolled with medication

          -  Pregnant or breast feeding women

          -  Dementia or altered mental status

          -  Known pre-existing clinically significant or uncontrolled disorder of the
             hypothalamic-pituitary axis, adrenal or thyroid glands

          -  Previous pericarditis

          -  Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as
             nausea,diarrhea,vomiting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2006</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Myeloid</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

